336 related articles for article (PubMed ID: 31923859)
41. Structure of WDR5 bound to mixed lineage leukemia protein-1 peptide.
Patel A; Dharmarajan V; Cosgrove MS
J Biol Chem; 2008 Nov; 283(47):32158-61. PubMed ID: 18829459
[TBL] [Abstract][Full Text] [Related]
42. Structural basis of nucleosome recognition and modification by MLL methyltransferases.
Xue H; Yao T; Cao M; Zhu G; Li Y; Yuan G; Chen Y; Lei M; Huang J
Nature; 2019 Sep; 573(7774):445-449. PubMed ID: 31485071
[TBL] [Abstract][Full Text] [Related]
43. MLL leukemia and future treatment strategies.
Marschalek R
Arch Pharm (Weinheim); 2015 Apr; 348(4):221-8. PubMed ID: 25740345
[TBL] [Abstract][Full Text] [Related]
44. Novel therapeutic strategies for MLL-rearranged leukemias.
Wong NM; So CWE
Biochim Biophys Acta Gene Regul Mech; 2020 Sep; 1863(9):194584. PubMed ID: 32534041
[TBL] [Abstract][Full Text] [Related]
45. Automethylation activities within the mixed lineage leukemia-1 (MLL1) core complex reveal evidence supporting a "two-active site" model for multiple histone H3 lysine 4 methylation.
Patel A; Vought VE; Swatkoski S; Viggiano S; Howard B; Dharmarajan V; Monteith KE; Kupakuwana G; Namitz KE; Shinsky SA; Cotter RJ; Cosgrove MS
J Biol Chem; 2014 Jan; 289(2):868-84. PubMed ID: 24235145
[TBL] [Abstract][Full Text] [Related]
46. Somatic cancer mutations in the MLL1 histone methyltransferase modulate its enzymatic activity and dependence on the WDR5/RBBP5/ASH2L complex.
Weirich S; Kudithipudi S; Jeltsch A
Mol Oncol; 2017 Apr; 11(4):373-387. PubMed ID: 28182322
[TBL] [Abstract][Full Text] [Related]
47. Discovery of M-808 as a Highly Potent, Covalent, Small-Molecule Inhibitor of the Menin-MLL Interaction with Strong
Xu S; Aguilar A; Huang L; Xu T; Zheng K; McEachern D; Przybranowski S; Foster C; Zawacki K; Liu Z; Chinnaswamy K; Stuckey J; Wang S
J Med Chem; 2020 May; 63(9):4997-5010. PubMed ID: 32338903
[TBL] [Abstract][Full Text] [Related]
48. The histone methyltransferase activity of MLL1 is dispensable for hematopoiesis and leukemogenesis.
Mishra BP; Zaffuto KM; Artinger EL; Org T; Mikkola HK; Cheng C; Djabali M; Ernst P
Cell Rep; 2014 May; 7(4):1239-47. PubMed ID: 24813891
[TBL] [Abstract][Full Text] [Related]
49. Design and synthesis of benzylpiperidine inhibitors targeting the menin-MLL1 interface.
Ren J; Xu W; Tang L; Su M; Chen D; Chen YL; Zang Y; Li J; Shen J; Zhou Y; Xiong B
Bioorg Med Chem Lett; 2016 Sep; 26(18):4472-4476. PubMed ID: 27528435
[TBL] [Abstract][Full Text] [Related]
50. A Molecular Switch between Mammalian MLL Complexes Dictates Response to Menin-MLL Inhibition.
Soto-Feliciano YM; Sánchez-Rivera FJ; Perner F; Barrows DW; Kastenhuber ER; Ho YJ; Carroll T; Xiong Y; Anand D; Soshnev AA; Gates L; Beytagh MC; Cheon D; Gu S; Liu XS; Krivtsov AV; Meneses M; de Stanchina E; Stone RM; Armstrong SA; Lowe SW; Allis CD
Cancer Discov; 2023 Jan; 13(1):146-169. PubMed ID: 36264143
[TBL] [Abstract][Full Text] [Related]
51. PHF20L1 antagonizes SOX2 proteolysis triggered by the MLL1/WDR5 complexes.
Wang Q; Yu M; Ma Y; Zhang X; Zhang H; Li S; Lan R; Lu F
Lab Invest; 2018 Dec; 98(12):1627-1641. PubMed ID: 30089852
[TBL] [Abstract][Full Text] [Related]
52. Inhibiting MLL1-WDR5 interaction ameliorates neuropathic allodynia by attenuating histone H3 lysine 4 trimethylation-dependent spinal mGluR5 transcription.
Lin TB; Lai CY; Hsieh MC; Ho YC; Wang HH; Yang PS; Cheng JK; Chen GD; Ng SC; Peng HY
Pain; 2020 Sep; 161(9):1995-2009. PubMed ID: 32345914
[TBL] [Abstract][Full Text] [Related]
53. Histone methyltransferase MLL1 drives renal tubular cell apoptosis by p53-dependent repression of E-cadherin during cisplatin-induced acute kidney injury.
Zhang C; Guan Y; Zou J; Yang X; Bayliss G; Zhuang S
Cell Death Dis; 2022 Sep; 13(9):770. PubMed ID: 36068197
[TBL] [Abstract][Full Text] [Related]
54. A conserved arginine-containing motif crucial for the assembly and enzymatic activity of the mixed lineage leukemia protein-1 core complex.
Patel A; Vought VE; Dharmarajan V; Cosgrove MS
J Biol Chem; 2008 Nov; 283(47):32162-75. PubMed ID: 18829457
[TBL] [Abstract][Full Text] [Related]
55. A role for WDR5 in integrating threonine 11 phosphorylation to lysine 4 methylation on histone H3 during androgen signaling and in prostate cancer.
Kim JY; Banerjee T; Vinckevicius A; Luo Q; Parker JB; Baker MR; Radhakrishnan I; Wei JJ; Barish GD; Chakravarti D
Mol Cell; 2014 May; 54(4):613-25. PubMed ID: 24793694
[TBL] [Abstract][Full Text] [Related]
56. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.
Ye J; Zha J; Shi Y; Li Y; Yuan D; Chen Q; Lin F; Fang Z; Yu Y; Dai Y; Xu B
Clin Epigenetics; 2019 Oct; 11(1):137. PubMed ID: 31590682
[TBL] [Abstract][Full Text] [Related]
57. The Cks1/Cks2 axis fine-tunes Mll1 expression and is crucial for MLL-rearranged leukaemia cell viability.
Grey W; Ivey A; Milne TA; Haferlach T; Grimwade D; Uhlmann F; Voisset E; Yu V
Biochim Biophys Acta Mol Cell Res; 2018 Jan; 1865(1):105-116. PubMed ID: 28939057
[TBL] [Abstract][Full Text] [Related]
58. Structure, function and inhibition of critical protein-protein interactions involving mixed lineage leukemia 1 and its fusion oncoproteins.
Li X; Song Y
J Hematol Oncol; 2021 Apr; 14(1):56. PubMed ID: 33823889
[TBL] [Abstract][Full Text] [Related]
59. The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia.
Baker A; Gregory GP; Verbrugge I; Kats L; Hilton JJ; Vidacs E; Lee EM; Lock RB; Zuber J; Shortt J; Johnstone RW
Cancer Res; 2016 Mar; 76(5):1158-69. PubMed ID: 26627013
[TBL] [Abstract][Full Text] [Related]
60. Non-canonical H3K79me2-dependent pathways promote the survival of MLL-rearranged leukemia.
Richter WF; Shah RN; Ruthenburg AJ
Elife; 2021 Jul; 10():. PubMed ID: 34263728
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]